当前位置:循环首页>正文

[GWICC2011]肥胖对心房颤动影响的争议

作者:  张树龙  缪丹丹   日期:2011/11/10 14:55:22

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

心房颤动(简称房颤)为临床上最常见的持续性快速心律失常,在美国Miyasaka等人报道经年龄和性别校正后房颤的发病率在1980年为3.03‰,2000年为3.68‰,21年来房颤发病率上升了12.6%[1]。房颤发病率的增加与多种因素有关,已被认知的房颤危险因素包括年龄、男性、高血压、瓣膜性心脏病、充血性心力衰竭、甲状腺疾病等[2],其中一个重要原因在于肥胖的患病率逐年增加。但是肥胖对房颤的影响仍存争议,故本文就肥胖与房颤的相关性作一综述。


  参考文献
  [1]Miyasaka Y,Barnes ME,Gersh BJ,et a1.Secular trends in incidence of atrial fibrillation in Olmsted County Minnesota, 1980 to 2000 and implications on the projections for future prevalence. Circulation,2006;114:l19-125.
  [2]Rosiak M, Dziuba M, Chudzik M,et al. Risk factors for atrial fibrillation: Not always severe heart disease, not always so ‘lonely’. Cardiology J,2010;17,5:437-442.
  [3]Wang TJ,Parise H,k vy D,et a1.Obesity and the risk of new-onset atrial fibrillation. JAMA,2004;292:2471-2477.
  [4]Wanahita N, Messerli FH, Bangalore S, et al. Atrial fibrillation and obesity results of a meta-analysis. Am Heart J, 2008;155:310–315.
  [5]Girerd N, Pibarot P, Fournier D, et al. Middle-aged men with increased waist circumference and elevated c-reactive protein level are at high risk of postoperative atrial fibrillation following coronary artery bypass grafting surgery. Eur Heart J,2009;30:1270–1278.
  [6]Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation,2007;116 (Supplement I):I213–I219.
  [7]Filardo G,Hamilton C,Hamman B,et al.Relation of obesity to atrial fibrillation after isolated coronary artery bypass grafting. Am J Cardiol, 2009;103:663–666.
  [8]Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med,2005;118(5):489–495.
  [9] Dublin S, French B, Glazer NL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med, 2006;166(21):2322–2328.
  [10]Tedrow UB, Cohen D, Ridker PM, et al. The long- and  short-term impact of elevated body mass index on the risk of new atrial fibrillation. J Am Coll Cardiol ,2010; 55:2319–2327.
  [11]Ayer JG, Almagragy HS, Patel AA, et al. Body mass index is an independent determinant of left atrial size. Heart Lung and Circ, 2008;17:19–24.
  [12]Nicolaou VN, Papadakis JE, Dermitzakis G, et al. Effect of obesity on atrial size in older women with nonvalvular paroxysmal atrial fibrillation. Aging Clin Exp Res, 2008, 21:344–348.
  [13] Kosar F, Aksoy Y, Ari F, et al. P-wave duration and dispersion in obese subjects. Ann Noninvasive Electrocardiol, 2008; 13:3–7.
  [14] Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation, 2001;104:2886–2891.
  [15]Lin YK, Chen YJ, Chen SA. Potential atrial arrhythmogenicity of adipocytes:implications of the genesis of atrial fibrillation. Med Hypotheses ,2010;74:1026–1029.
  [16]Cha YM, Friedman PA, Asirvatham SJ, et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation ,2008;117:2583–2590.
  [17]Chilukuri K, Dalal D, Gadrey S, et al. A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol,2010;21:521–525.
  [18]Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease.  Am J Med, 2007;120:863-870.
  [19]Lavie CJ, Milani RV, Ventura HO. Obesity, heart disease, and favorable prognosis—truth or paradox?  Am J Med, 2007;120:825-826.
  [20]Galal W, van Gestel YR, Hoeks SE, et al. The obesity paradox in patients with peripheral arterial disease. Chest, 2008;134:925-930.
  [21]Lavie CJ, Ventura HO, Milani RV. The “obesity paradox”: is smoking/lung disease the explanation? Chest, 2008;134:896-898.
  [22]Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease:risk factor, paradox, and impact of weight loss. J Am Coll Cardiol, 2009;53:1925-1932.
  [23]McAuley P, Myers J, Abella J,et al. Body mass, fitness and survival in veteran patients: another obesity paradox? Am J Med,2007;120:518-524.
  [24]Badheka AO, Rathod A, Kizilbash MA,et al.Influence of obesity on outcomes in atrial fibrillation:yet another obesity paradox. Am J Med,2010;123:646-651.
  [25] Horwich TB, Fonarow GC. Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis. COPD,and AIDS, Semin Dial, 2007;20:549-553.
  [26]Kalantar-Zadeh K, Block G, Humphreys MH,et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int,2003;63:793-808.
  [27]Issac TT, Dokainish H, Lakkis NM. Role of inflammation ininitiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol,2007;50:2021-2028.
  [28]Lee SH, Chen YC, Chen YJ, et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes.  Life Sci ,2007 ;80:1806-1815.
  [29]Sawaya SE, Rajawat YS, Rami TG, et al. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Heart Circ Physiol,2007;292:H1561-H1567.
  [30]Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol, 1999;277:E971-E975.
  [31]Novo G, Guttilla D, Fazio G, et al. The role of the  renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol, 2008;66:345-351.
  [32]Weber MA, Neutel JM, Smith DH. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol, 2001;37:169-174.
  [33]Rossi A, Enriquez-Sarano M, Burnett JC Jr, et al. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic Study. J Am Coll Cardiol, 2000;35:1256-1262.
  [34]Rienstra M, Van Gelder IC, Van den Berg MP, et al. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NTpro) BNP. Europace, 2006;8:482-487.
  [35]Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation, 2004;109:594-600.
  [36]Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet, 2000;356(9233):930-933.
  [37]Boos CJ, Lip GY, Jilma B. Endotoxemia, inflammation, and atrial fibrillation. Am J Cardiol, 2007;100:986-988.
  [38]Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol,2001;38:789-795.
  [39]Niraj A, Pradhan J, Fakhry H, et al. Severity of coronary artery disease in obese patients undergoing coronary angiography: “obesity paradox”revisited. Clin Cardiol, 2007;30:391-396.

上一页  [1]  [2]  

版面编辑:赵书芳  责任编辑:郭淑娟



肥胖心房颤动房颤

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530